Previous studies supported a role of PON1 in atheroprotection, through its ability to prevent lipid oxidation and limit atherosclerotic lesion development; moreover, low PON1 activity has been associated with different cardiovascular pathologies, including atherosclerosis and AAA [113,114,115,116,117]. Here, PON1 is linked to triple-A syndrome.